COVID-19 (SARS-CoV-2 infection) related pneumonia Infections and Infestations
Conditions
Interventions
From 11/06/2020, patients were treated with dexamethasone 6 mg QD for seven to 10 days if they required oxygen.
After 15/09/2020, the clinic's protocol was modified to use methylpredn
Sponsors
Clínica Medellín - Grupo Quirónsalud
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Over 18 years of age 2. Hospitalized with COVID-19 pneumonia confirmed by positive Real-Time Reverse Transcription Polymerase Chain Reaction for SARS-CoV2 (RT-PCR SARS-CoV-2) by Berlin protocol 3. Radiological confirmation of pneumonia
Exclusion criteria
Exclusion criteria: 1. Contraindications associated with corticosteroids 2. Dissent for medical management 3. Death in the first 24 hours 4. Patient in palliative care or with a life expectancy of fewer than 6 months 5. If the patient required admission to the ICU and did not receive at least two doses of the corticosteroid 6. If the patient receives at least two doses of methylprednisolone but did not continue with prednisone, they were not included, but their outcome continued to be monitored 7. Patients who also received less than 2 days of dexamethasone treatment were withdrawn from study follow-up
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recovery time measured in days using patient records; recovery time determined as the time until hospital discharge when each of the following criteria were met: decrease in laboratory severity markers, improvement in symptoms, decrease in oxygen requirement until nasal cannula or supplementary oxygen removal, and at least two doses of the respective treatment have been received | — |
Secondary
| Measure | Time frame |
|---|---|
| Respiratory health measured using arterial blood gas results during the period of hospitalization (Cytokine Release Syndrome (CRS) defined as ventilatory impairment plus two of the following: C-reactive protein (CRP) greater than 10 mg/dl, serum ferritin greater than 1000 ng/ml, D-dimer greater than 900 ng/ml) | — |
Countries
Colombia
Outcome results
None listed